Research
- Research
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHB Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
Orphan Drugs Sound Small but Can Lead to Big Drug Spending
December 11, 2021
The OIG report is evidence that the Orphan Drug Act is not working as intended. OIG looked at the 20...
December 11, 2021
Mail-service pharmacy is a convenient, reliable, and affordable option for patients to safely access prescription drugs....
Drug Manufacturer Strategies for Keeping Drug Costs High
November 16, 2021
The research firm Visante examines certain drug manufacturer anti-competitive tactics that affect many different types of prescription drugs. For example,...
Understanding Differences Between The Number of Pharmacies Reported by NCPA and NCPDP
October 29, 2021
Over the last several years, it has become increasingly apparent that there is a growing data discrepancy between reports that...
Mandating Pharmacy Reimbursement Will Increase Prescription Drug Spending
August 31, 2021
A new report, Mandating Pharmacy Reimbursement Will Increase Prescription Drug Spending, examines how paying pharmacies more for dispensing medications will...
Mandating Pharmacy Reimbursement Will Increase Prescription Drug Spending
August 11, 2021
The average dispensing fee in the commercial market is currently less than $2, while in comparison, $10.50 is a common...
Nationwide, More Independent Pharmacies Opened in 2020
July 16, 2021
During the COVID-19 pandemic, the net number of retail independent pharmacies nationwide increased. The recent increases in the number of...
Biosimilars Versus Biologics – How About Both?
July 11, 2021
Pharmacy benefit managers (PBMs) are using the availability of alternatives, both biosimilars and their reference biologics, as part of an...
DELIVERY OF BIOSIMILARS TO PATIENTS CONCENTRATED IN NON-RETAIL SETTINGS
July 11, 2021
Most biosimilars are mainly available to patients as provider-administered infusions in institutional settings such as hospitals and doctors’ offices and...
BIOSIMILARS COMPETITION REDUCE COSTS
July 11, 2021
After biosimilars launch, reference biologics’ list price increases stop and net costs fall. Currently, 7 reference biologics have at least...
“Patent Thickets” are Anti-Competitive and Lead to Higher Drug Costs
May 11, 2021
Brand drug manufacturers extend the exclusivity of their drugs beyond the end of their initial exclusivity period by filing multiple...
Brand Drug Manufacturers’ Anti-Competitive Behavior: Patent Thicket
May 11, 2021
Brand drug manufacturers use a variety of strategies to extend the exclusivity of their drugs beyond the end of their...